Efficacy of medical grade honey in the management of canine otitis externa – a pilot study

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

In vitroefficacy of a honey‐based gel against canine clinical isolates ofStaphylococcus pseudintermediusandMalassezia pachydermatis

Oliveira

Devesa

Hill

2018

“…In the veterinary literature, there are several studies investigating the clinical efficacy of antibiotic/antifungal/corticosteroid combination ear products, but none of them have used the validated otitis scoring scale OTI‐3, pruritus VAS scale or the semiquantitative cytology scale described by Budach & Mueller, so that comparisons are not possible . Although some of these studies used an otic cytology scale described by Ginel et al ., we preferred to use the one by Budach & Mueller because it has been validated independently . A pilot study on the use of medical grade honey in 15 dogs affected by acute bacterial and/or yeast otitis reported on the use of the OTI‐3 scale.…”

Section: Discussionmentioning

confidence: 99%

“…A pilot study on the use of medical grade honey in 15 dogs affected by acute bacterial and/or yeast otitis reported on the use of the OTI‐3 scale. It reported an initial mean score lower than that of our study (5 versus 6), but a similar improvement curve, confirming that clinical resolution of otitis may occur within 2 weeks of starting treatment …”

Section: Discussionmentioning

confidence: 99%

Impact of a terbinafine–florfenicol–betamethasone acetate otic gel on the quality of life of dogs with acute otitis externa and their owners

Noli¹,

Sartori²,

Cena

2017

Background -Treatment of canine otitis externa with owner-administered products can be difficult.Objectives -To evaluate otic treatment administered by a veterinarian on quality of life (QoL) of dogs with otitis externa and their owners, and on clinical and cytology parameters of otitis; compared to an owner-administered treatment.Animals -Fifty client-owned dogs randomly randomized into two groups and treated for 2 weeks.Methods -Veterinarians treated Group A dogs with a veterinary licensed otic gel on two occasions at a 1 week interval; owners treated Group B dogs once daily with a veterinary licensed otic drop based product along with twice weekly cleaning. Veterinarians evaluated otitis with the OTI-3 scale and semi-quantitative cytological examination on days 0, 7, 14 and 28. At each visit, owners assessed QoL with a validated questionnaire and pruritus with a Visual Analog Scale. Scores before and after treatment of each group, and differences between groups were analysed statistically.Results -In both groups, all parameters improved significantly. There was a significantly higher improvement of QoL scores, for dogs and owners, in Group A, compared to Group B at all time points (P < 0.05), except for owner QoL on Day 28. There was no difference in improvement of OTI-3 between groups at any time point, whereas Group A cytology scores and pruritus improved significantly more by Day 7 (P = 0.0026 and P = 0.0294, respectively).Conclusion -A veterinarian-administered otic gel provided equivalent efficacy and higher QoL to dogs with otitis externa and their owners, compared to an owner-administered topical otic therapy.

“…39,40 MGH1 previously has been evaluated in a pilot clinical trial which reported favourable antibacterial potential in canine otitis externa. 41 In addition, MGH1 has been evaluated in vitro reiterating its antifungal and antibacterial properties via a hydrogen peroxide-independent action. 2 In that study, MGH1 was compared to honey, showing that MGH1 had a significantly stronger bactericidal effect than honey alone against S. pseudintermedius isolates (P = 0.003).…”

Section: Discussionmentioning

confidence: 99%

In vitro antimicrobial efficacy of two medical grade honey formulations against common high‐risk meticillin‐resistant staphylococci and Pseudomonas spp. pathogens

Cremers¹,

Belas

Costa

et al. 2019

Self Cite

Background Antimicrobial resistance is a problem in human and animal healthcare. Honey may be used for its wound healing properties and antimicrobial effects. Objective To investigate the antimicrobial activity of two commercially available medical grade honeys (MGHs) against Staphylococcus spp. and Pseudomonas spp. isolates. Methods and materials Two formulations, MGH1 (40% w/v honey) and MGH2 (80% w/v Manuka honey), were tested in vitro for minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) against 11 Staphylococcus and 11 Pseudomonas isolates at low [1.5 × 104 colony forming units (cfu)/well] and high (1.5 × 106 cfu/well) concentrations of inoculum, representing systemic and cutaneous bacterial loads during infection, respectively. Results MGH2 showed a lower MIC against staphylococci than MGH1, although this was not statistically significant. MGH1 had stronger bactericidal effects against staphylococci than MGH2, although this effect was statistically significant only at the higher bacterial concentration (P < 0.01). For Pseudomonas spp., MGH1 had significantly higher antimicrobial activity (both MIC and MBC) than MGH2 against all isolates tested and at both bacterial concentrations (P < 0.05). Conclusions and clinical importance Both MGHs were effective in vitro against common cutaneous pathogens including meticillin‐resistant staphylococci and Pseudomonas species. The higher efficacy of the MGH1 formulation against Pseudomonas and its consistent effects against staphylococci, while containing only half of the amount of honey compared to MGH2, invites further investigation of the mechanisms and clinical applications of MGH1.